Krystal Biotech (NASDAQ:KRYS) Sets New 1-Year High – Should You Buy?

Krystal Biotech, Inc. (NASDAQ:KRYS)’s stock price reached a new 52-week high on Thursday . The stock traded as high as $358.45 and last traded at $360.93, with a volume of 67579 shares changing hands. The stock had previously closed at $347.63.

Analyst Ratings Changes

Several analysts recently issued reports on KRYS shares. Evercore reiterated an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Weiss Ratings raised shares of Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday, June 16th. HC Wainwright lifted their price objective on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research note on Tuesday, June 16th. Wall Street Zen lowered shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, TD Cowen upped their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $340.56.

Krystal Biotech Price Performance

The stock has a market capitalization of $10.50 billion, a price-to-earnings ratio of 47.37 and a beta of 0.53. The firm has a fifty day moving average of $300.85 and a 200 day moving average of $275.14.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The firm had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. Research analysts predict that Krystal Biotech, Inc. will post 7.66 EPS for the current year.

Insider Buying and Selling at Krystal Biotech

In related news, EVP John Charles Thomas sold 642 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total value of $193,903.26. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently made changes to their positions in the business. Pacer Advisors Inc. lifted its holdings in Krystal Biotech by 48.8% during the 1st quarter. Pacer Advisors Inc. now owns 2,547 shares of the company’s stock worth $658,000 after buying an additional 835 shares during the last quarter. Empowered Funds LLC increased its holdings in shares of Krystal Biotech by 165.3% during the first quarter. Empowered Funds LLC now owns 2,276 shares of the company’s stock valued at $588,000 after purchasing an additional 1,418 shares during the period. Seven Fleet Capital Management LP raised its stake in shares of Krystal Biotech by 7.9% during the first quarter. Seven Fleet Capital Management LP now owns 4,316 shares of the company’s stock valued at $1,115,000 after purchasing an additional 316 shares in the last quarter. Western Wealth Management LLC acquired a new stake in Krystal Biotech in the first quarter worth about $34,000. Finally, Bank of America Corp DE grew its position in Krystal Biotech by 36.6% in the 1st quarter. Bank of America Corp DE now owns 260,647 shares of the company’s stock valued at $67,330,000 after buying an additional 69,840 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.